KR20100055453A - 홍반을 치료하기 위한 개선된 브리모니딘 조성물 - Google Patents

홍반을 치료하기 위한 개선된 브리모니딘 조성물 Download PDF

Info

Publication number
KR20100055453A
KR20100055453A KR1020107005023A KR20107005023A KR20100055453A KR 20100055453 A KR20100055453 A KR 20100055453A KR 1020107005023 A KR1020107005023 A KR 1020107005023A KR 20107005023 A KR20107005023 A KR 20107005023A KR 20100055453 A KR20100055453 A KR 20100055453A
Authority
KR
South Korea
Prior art keywords
composition
gel
skin
erythema
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107005023A
Other languages
English (en)
Korean (ko)
Inventor
클라우스 테오발트
크리스토퍼 브이. 포알라
Original Assignee
갈더마 라보라토리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈더마 라보라토리즈 인코포레이티드 filed Critical 갈더마 라보라토리즈 인코포레이티드
Publication of KR20100055453A publication Critical patent/KR20100055453A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107005023A 2007-08-31 2008-08-29 홍반을 치료하기 위한 개선된 브리모니딘 조성물 Ceased KR20100055453A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
US60/967,191 2007-08-31

Publications (1)

Publication Number Publication Date
KR20100055453A true KR20100055453A (ko) 2010-05-26

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107005023A Ceased KR20100055453A (ko) 2007-08-31 2008-08-29 홍반을 치료하기 위한 개선된 브리모니딘 조성물

Country Status (12)

Country Link
US (3) US20090061020A1 (https=)
EP (1) EP2200617A4 (https=)
JP (1) JP2010537988A (https=)
KR (1) KR20100055453A (https=)
CN (2) CN102552112A (https=)
AR (1) AR068816A1 (https=)
AU (1) AU2008296948A1 (https=)
BR (1) BRPI0816097A2 (https=)
CA (1) CA2698680A1 (https=)
MX (1) MX2010002392A (https=)
NO (1) NO20100301L (https=)
WO (1) WO2009032223A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2010136585A2 (en) * 2009-05-29 2010-12-02 Galderma Research & Development Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
MX2012010823A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
KR20130101552A (ko) * 2010-10-21 2013-09-13 갈데르마 소시에떼아노님 국소용 겔 조성물
BR112013020770A2 (pt) 2011-02-15 2019-08-27 Allergan, Inc. composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
PH12014500783A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
MX379253B (es) 2014-06-11 2025-03-11 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos.
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
JP5580210B2 (ja) * 2007-12-21 2014-08-27 ガルデマ ラボラトリーズ インコーポレイテッド 手術前治療

Also Published As

Publication number Publication date
CN102552112A (zh) 2012-07-11
CN101808645A (zh) 2010-08-18
AU2008296948A1 (en) 2009-03-12
NO20100301L (no) 2010-03-25
CA2698680A1 (en) 2009-03-12
MX2010002392A (es) 2010-07-28
BRPI0816097A2 (pt) 2016-11-01
EP2200617A4 (en) 2011-01-12
WO2009032223A1 (en) 2009-03-12
EP2200617A1 (en) 2010-06-30
US20120040016A1 (en) 2012-02-16
AR068816A1 (es) 2009-12-09
US20120282346A1 (en) 2012-11-08
JP2010537988A (ja) 2010-12-09
US20090061020A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
KR20100055453A (ko) 홍반을 치료하기 위한 개선된 브리모니딘 조성물
RU2587041C2 (ru) Способ предотвращения или лечения опухоли кожи
ES2376172T5 (es) Compuestos, formulaciones y métodos para tratar o prevenir la rosácea
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
CA2792646C (en) Improved uses and compositions for safe and effective treatment of erythema
US20180360827A1 (en) Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
JP2010537988A5 (https=)
US9504661B2 (en) Dapsone to treat rosacea
KR20100099191A (ko) 수술전 처리
JP2016525553A (ja) 皮膚肥厚の治療法
JP2014530846A (ja) ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法
WO2012001064A2 (en) Method for preventing or treating skin tumor
US20190021995A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
HK1175698A1 (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
HK1175698B (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
HK1180208A (en) Compositions comprising brimonidine for the treatment of erythema
HK1180208B (en) Compositions comprising brimonidine for the treatment of erythema

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100305

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150102

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I